Shares of EyeGate Pharmaceuticals Inc. EYEG, +74.74% rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contact lens, in patients in need of corneal wound repair. EyeGate plans to submit a de novo application to the Food and Drug Administration in the first six months of 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,